Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

por Goldsmith, David, Dellanna, Frank, Schiestl, Martin, Krendyukov, Andriy, Combe, Christian
Publicado 2018

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study

por Locatelli, Francesco, Spasovski, Goce, Dimkovic, Nada, Wanner, Christoph, Dellanna, Frank, Pontoriero, Giuseppe
Publicado 2014

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience

por Dellanna, Frank, Goldsmith, David, Krendyukov, Andriy, Seidl, Andreas, Höbel, Nadja, Combe, Christian
Publicado 2017

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of F...

por Barratt, Jonathan, Dellanna, Frank, Portoles, Jose, Choukroun, Gabriel, De Nicola, Luca, Young, James, Dimković, Nada, Reusch, Michael
Publicado 2023

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study

por London, Gérard, Mann, Johannes, Goldsmith, David, Combe, Christian, Dellanna, Frank , Zaoui, Philippe, Hoebel, Nadja, Krendyukov, Andriy, MacDonald, Karen, Abraham, Ivo
Publicado 2018

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

por Combe, Christian, Mann, Johannes, Goldsmith, David, Dellanna, Frank, Zaoui, Philippe, London, Gérard, Denhaerynck, Kris, Krendyukov, Andriy, Abraham, Ivo, MacDonald, Karen
Publicado 2019

Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Resu...

por Galle, Jan, Kleophas, Werner, Dellanna, Frank, Schmid, Volkmar H.R., Forkel, Claudia, Dikta, Gerhard, Krajewski, Vera, Fuchs, Winfried, Forst, Thomas, Pfützner, Andreas
Publicado 2012

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

por Coyne, Daniel W., Singh, Hem N., Smith, William T., Giuseppi, Ana Carolina, Connarn, Jamie N., Sherman, Matthew L., Dellanna, Frank, Malluche, Hartmut H., Hruska, Keith A.
Publicado 2019

Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITO...

por Gesualdo, Loreto, Combe, Christian, Covic, Adrian, Dellanna, Frank, Goldsmith, David, London, Gérard, Mann, Johannes F., Zaoui, Philippe, Turner, Matthew, Muenzberg, Mike, MacDonald, Karen, Abraham, Ivo
Publicado 2015

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis

por Renders, Lutz, Budde, Klemens, Rosenberger, Christian, van Swelm, Rachel, Swinkels, Dorine, Dellanna, Frank, Feuerer, Werner, Wen, Ming, Erley, Christiane, Bader, Birgit, Sommerer, Claudia, Schaier, Matthias, Meurer, Karoline, Matis, Louis
Publicado 2019

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemod...

por Girndt, Matthias, Plüer, Manfred, Dellanna, Frank, Michelsen, Ann K., Beige, Joachim, Toussaint, Kai, Wehweck, Hubert J., Koch, Michael, Hafezi Rachti, Syrus, Faust, Justus, Bosselmann, Hans-Peter, Witzke, Oliver, Janssen, Robert S.
Publicado 2022